Sanofi has bought the rights to Arrowhead Pharmaceuticals first-in-class RNA interference (RNAi) therapeutic candidate for hypertriglyceridemia in Greater China. Under the agreement, Sanofi will pay $130 million upfront and up to $265 million in potential regulatory milestones to Visirna Therapeutics, a majority-owned subsidiary of Arrowhead. The investigational drug plozasiran is designed to reduce production of […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!